Your browser is no longer supported. Please, upgrade your browser.
Settings
MNTA Momenta Pharmaceuticals, Inc. daily Stock Chart
MNTA [NASD]
Momenta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own1.30% Shs Outstand74.72M Perf Week7.91%
Market Cap1.02B Forward P/E- EPS next Y-1.40 Insider Trans-8.31% Shs Float71.28M Perf Month-1.80%
Income-60.30M PEG- EPS next Q-0.06 Inst Own97.10% Short Float10.50% Perf Quarter-13.88%
Sales108.50M P/S9.40 EPS this Y76.80% Inst Trans-0.69% Short Ratio9.14 Perf Half Y-10.49%
Book/sh4.83 P/B2.83 EPS next Y-18.60% ROA-11.80% Target Price13.67 Perf Year-6.02%
Cash/sh5.60 P/C2.44 EPS next 5Y- ROE-16.20% 52W Range11.85 - 19.90 Perf YTD-9.30%
Dividend- P/FCF25.56 EPS past 5Y-15.80% ROI-20.10% 52W High-31.41% Beta1.68
Dividend %- Quick Ratio4.20 Sales past 5Y-17.30% Gross Margin- 52W Low15.19% ATR0.66
Employees290 Current Ratio4.20 Sales Q/Q-17.20% Oper. Margin- RSI (14)47.32 Volatility5.36% 5.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-74.40% Profit Margin-55.60% Rel Volume0.56 Prev Close13.20
ShortableYes LT Debt/Eq0.00 EarningsNov 01 BMO Payout- Avg Volume819.09K Price13.65
Recom3.00 SMA201.71% SMA50-7.75% SMA200-11.66% Volume458,924 Change3.41%
Oct-05-17Downgrade Stifel Buy → Hold $22 → $15
Sep-28-17Initiated Goldman Neutral $18
May-22-17Downgrade Barclays Overweight → Equal Weight $20 → $17
Feb-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-31-17Reiterated Barclays Overweight $19 → $20
Nov-22-16Initiated Aegis Capital Hold
Oct-11-16Upgrade Barclays Equal Weight → Overweight $13 → $19
Sep-07-16Downgrade Maxim Group Hold → Sell $6
Jun-06-16Initiated Goldman Neutral $14
Jan-08-16Upgrade Maxim Group Sell → Hold
Nov-13-15Initiated JP Morgan Overweight
Aug-06-15Downgrade Goldman Buy → Neutral
Jun-19-15Reiterated Stifel Buy $26 → $29
Jun-19-15Reiterated Brean Capital Buy $25 → $31
Jun-04-15Initiated Stifel Buy $26
Apr-17-15Reiterated Leerink Partners Outperform $16 → $24
Apr-17-15Reiterated Brean Capital Buy $15 → $25
Feb-18-15Reiterated UBS Buy $18 → $15
Jan-23-15Downgrade Maxim Group Buy → Sell $17 → $7
Jan-08-15Initiated Brean Capital Buy $15
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-17-17 08:08AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-15-17 12:07PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 15, 2017 Capital Cube
Nov-10-17 03:30PM  Momenta Pharmaceuticals, Inc.'s Rough Month Motley Fool
08:07AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-08-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-03-17 09:59AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 03:56PM  Edited Transcript of MNTA earnings conference call or presentation 1-Nov-17 2:00pm GMT Thomson Reuters StreetEvents
03:12PM  Teva Pharmaceutical Industries Ltd -- Moody's says Teva's US generics business will face increased price pressure in 2018; a credit negative Moody's
02:59PM  Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Momenta Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-01-17 04:30PM  Why Momenta Pharmaceuticals Fell 12.6% Today Motley Fool -12.59%
09:24AM  Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers TheStreet.com
08:29AM  Momenta shares plunge 14% on Q3 profit, revenue misses MarketWatch
08:13AM  Momenta reports 3Q loss Associated Press
08:05AM  Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept) GlobeNewswire
Oct-30-17 12:04PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017 Capital Cube
Oct-19-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-18-17 09:52AM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 18, 2017 Capital Cube
08:00AM  Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast GlobeNewswire
Oct-17-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-16-17 09:45AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-12-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-06-17 10:57AM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 6, 2017 Capital Cube -6.16%
Oct-05-17 11:16AM  Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early Zacks -8.61%
09:30AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
08:39AM  Mylans surprise generic win sends Teva, Momenta shares plunging MarketWatch
08:20AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : October 5, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals ACCESSWIRE
Oct-04-17 04:44PM  Why Shopify, Momenta Pharmaceuticals, and MBIA Slumped Today Motley Fool -13.71%
04:11PM  How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge Investor's Business Daily
12:28PM  A Generic Drug Face-Off Sends Mylan Soaring 19% Motley Fool
09:33AM  Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg Zacks
08:06AM  Momenta Pharmaceuticals Inc (MNTA): What Does It Mean For Your Portfolio? Simply Wall St.
Oct-03-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-02-17 04:05PM  Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer GlobeNewswire
Sep-29-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-27-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit +5.08%
Sep-25-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-22-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-12-17 07:30AM  Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors PR Newswire
Sep-07-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-06-17 08:09AM  Momenta (MNTA) Up 5.8% Since Earnings Report: Can It Continue? Zacks
Sep-01-17 09:58AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : September 1, 2017 Capital Cube
Aug-30-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-23-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-16-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-12-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-11-17 08:17PM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : August 12, 2017 Capital Cube
07:21PM  Edited Transcript of MNTA earnings conference call or presentation 2-Aug-17 2:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:22AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : August 10, 2017 Capital Cube
08:07AM  IHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-03-17 05:04PM  Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat Zacks
03:52PM  Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter Motley Fool
Aug-02-17 10:43PM  Momenta reports 2Q loss Associated Press
08:13AM  Momenta reports 2Q loss Associated Press
08:00AM  Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-28-17 09:37AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : July 28, 2017 Capital Cube
Jul-21-17 03:03PM  U.S. jury sides with Amphastar over Momenta in drug patent trial Reuters
03:00PM  Jury nixes Momenta patent case that sought $938M in damages American City Business Journals
02:17PM  Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar GlobeNewswire
12:41PM  U.S. jury sides with Amphastar over Momenta in drug patent trial Reuters
Jul-19-17 08:00AM  Momenta Pharmaceuticals Announces Date of Second Quarter 2017 Financial Results Conference Call and Webcast GlobeNewswire
Jul-10-17 02:53PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : July 10, 2017 Capital Cube
Jun-27-17 03:26PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 27, 2017 Capital Cube
Jun-15-17 12:15PM  Mylan In FDA Limbo On Generic Multiple Sclerosis Drug Investor's Business Daily
Jun-13-17 08:53AM  Implied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options Zacks
Jun-12-17 02:14PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 12, 2017 Capital Cube
Jun-09-17 09:23AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
Jun-07-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire +5.74%
Jun-05-17 04:17AM  Why Is Momenta Pharmaceuticals (MNTA) Down 9.7% Since the Last Earnings Report? Zacks
Jun-01-17 08:00AM  Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer GlobeNewswire
May-31-17 11:44AM  Novartis CEO sees no need for big takeover Reuters
May-10-17 04:05PM  UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences GlobeNewswire -5.31%
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences GlobeNewswire
May-04-17 03:25PM  Edited Transcript of MNTA earnings conference call or presentation 2-May-17 2:00pm GMT Thomson Reuters StreetEvents
May-03-17 04:19PM  Momenta Pharmaceuticals, Inc. Looks for Some Momentum Motley Fool
10:32AM  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat Zacks
May-02-17 05:23PM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : May 2, 2017 Capital Cube +7.14%
08:07AM  Momenta reports 1Q loss Associated Press
08:00AM  Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire
07:55AM  Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-01-17 08:09AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : May 1, 2017 Capital Cube
Apr-26-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-18-17 08:00AM  Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast GlobeNewswire
Mar-29-17 07:00AM  Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report? Zacks
07:00AM  Why Is Momenta (MNTA) Down 9.6% Since the Last Earnings Report? at Investopedia
Mar-24-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic Group of Companies, Inc. PR Newswire
Mar-17-17 04:06PM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
Mar-08-17 07:52AM  MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Mar-07-17 11:09AM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA PR Newswire
Mar-02-17 01:04PM  MOMENTA PHARMACEUTICALS INC Financials
Feb-28-17 03:29PM  FDA warns Pfizer over contaminated drugs at Kansas plant Reuters
08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-24-17 04:56PM  MOMENTA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
11:28AM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
10:30AM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors Business Wire
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WHEELER CRAIG APresident & CEONov 10Sale13.251,85224,539258,602Nov 14 02:09 PM
Leicher BruceSVP & General CounselNov 10Sale13.073554,640173,322Nov 14 02:07 PM
Kaundinya Ganesh VenkataramanCOO & CSONov 10Sale13.123925,143488,029Nov 14 02:05 PM
WHEELER CRAIG APresidentSep 28Option Exercise7.4125,667190,192286,121Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 28Sale19.0210,000190,200282,638Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 28Sale19.0325,667488,443260,454Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 01Option Exercise7.4114,167104,977274,621Sep 05 03:57 PM
WHEELER CRAIG APresidentSep 01Sale17.004507,650292,638Sep 05 03:57 PM
WHEELER CRAIG APresidentSep 01Sale17.0014,167240,839260,454Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Option Exercise7.412,30017,043262,754Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Sale17.003,45058,650293,088Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Sale17.002,30039,100260,454Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 21Sale15.074,11662,008267,173Aug 23 04:36 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 21Sale15.2082112,479488,421Aug 23 04:31 PM
Leicher BruceSVP & General CounselAug 21Sale15.2080212,190173,677Aug 23 04:28 PM
WHEELER CRAIG APresidentAug 10Option Exercise7.419,10067,431282,242Aug 14 02:51 PM
Leicher BruceSVP & General CounselAug 10Sale16.603505,810174,479Aug 14 02:59 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 10Sale16.603876,424489,242Aug 14 02:55 PM
WHEELER CRAIG APresidentAug 10Sale17.006,000102,000289,819Aug 14 02:51 PM
WHEELER CRAIG APresidentAug 10Sale16.9110,953185,219271,289Aug 14 02:51 PM
WHEELER CRAIG APresidentAug 02Option Exercise7.41100741279,961Aug 04 03:31 PM
WHEELER CRAIG APresidentAug 02Sale17.001001,700289,100Aug 04 03:31 PM
WHEELER CRAIG APresidentAug 02Sale17.001001,700279,861Aug 04 03:31 PM
Leicher BruceSVP & General CounselMay 22Sale14.8085912,713174,342May 23 02:47 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 19Sale15.9082113,054489,629May 23 02:51 PM
WHEELER CRAIG APresidentMay 19Sale15.834,11665,156279,861May 23 02:49 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 10Sale16.003846,144490,453May 12 02:13 PM
Leicher BruceSVP & General CounselMay 10Sale16.003475,552175,205May 12 02:14 PM
WHEELER CRAIG APresidentMay 10Sale15.771,85229,206283,977May 12 02:13 PM
WHEELER CRAIG APresidentFeb 22Sale15.515,62687,259301,365Feb 24 06:35 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 22Sale15.601,06916,676490,837Feb 24 06:24 PM
Leicher BruceSVP & General CounselFeb 22Sale15.601,05016,380175,552Feb 24 06:19 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchFeb 10Sale18.901,75633,188491,906Feb 14 05:42 PM
Leicher BruceSVP & General CounselFeb 10Sale18.901,62030,618176,602Feb 14 05:33 PM
WHEELER CRAIG APresidentFeb 10Sale18.857,088133,609306,991Feb 14 05:38 PM
Leicher BruceSVP & General CounselJan 31Sale18.005,00090,000178,222Feb 02 03:54 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchJan 09Option Exercise9.4539,647374,784493,662Jan 10 03:34 PM
Shea Richard PSVP, CFODec 15Sale15.009,799146,985119,906Dec 16 03:41 PM
Shea Richard PSVP, CFODec 09Sale15.001,45121,765129,705Dec 12 04:32 PM
WHEELER CRAIG APresidentNov 22Sale14.051,76424,784320,699Nov 23 10:52 AM
Shea Richard PSVP, CFONov 22Sale14.402273,269131,156Nov 23 10:46 AM
Roach James M.Senior VP, Development and ChiNov 22Sale14.402503,600155,381Nov 23 10:41 AM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchNov 22Sale14.402273,269454,015Nov 23 10:36 AM
Leicher BruceSVP & General CounselNov 22Sale14.402273,269182,576Nov 23 10:32 AM